Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionJanney Montgomery Scott LLC
Latest Disclosed Ownership84,324 shares
Latest Disclosed Value $ 37,654
Janney Montgomery Scott LLC reports 19.86% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 22, 2026 - Janney Montgomery Scott LLC filed a 13F-HR form disclosing ownership of 84,324 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $37,654,039 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 70,353 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 19.86% during the quarter. The current value of the position is $37,678,493 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-22 2026-03-31 13F VERTEX PHARMS Common Stock 92532F100 84,324 13,971 19.86 38 19.35 0.0932
2026-02-11 2025-12-31 13F VERTEX PHARMS Common Stock 92532F100 70,353 -7,103 -9.17 32 3.33 0.0732
2025-10-27 2025-09-30 13F VERTEX PHARMS Common Stock 92532F100 77,456 5,566 7.74 30 -6.25 0.0719
2025-07-17 2025-06-30 13F VERTEX PHARMS Common Stock 92532F100 71,890 3,271 4.77 32 -3.03 0.0836
2025-04-17 2025-03-31 13F VERTEX PHARMS Common Stock 92532F100 68,619 -23,573 -25.57 33 -10.81 0.0943
2025-01-17 2024-12-31 13F VERTEX PHARMS Common Stock 92532F100 92,192 -35,233 -27.65 37 -37.29 0.1029
2024-10-29 2024-09-30 13F VERTEX PHARMS Common Stock 92532F100 127,425 -2,384 -1.84 59 -1.67 0.1654
2024-07-25 2024-06-30 13F VERTEX PHARMS Common Stock 92532F100 129,809 7,553 6.18 61 17.65 0.1855
2024-05-01 2024-03-31 13F VERTEX PHARMS Common Stock 92532F100 122,256 -6,114 -4.76 51 -1.92 0.1520
2024-02-08 2023-12-31 13F VERTEX PHARMS Common Stock 92532F100 128,370 7,176 5.92 52 23.81 0.1695
2023-11-08 2023-09-30 13F VERTEX PHARMS Common Stock 92532F100 121,194 -4,819 -3.82 42 -4.55 0.1571
2023-07-26 2023-06-30 13F VERTEX PHARMS Common Stock 92532F100 126,013 838 0.67 44 12.82 0.1547
2023-04-28 2023-03-31 13F VERTEX PHARMS Common Stock 92532F100 125,175 -3,409 -2.65 39 5.41 0.1610
2023-02-01 2022-12-31 13F VERTEX PHARMS Common Stock 92532F100 128,584 21,258 19.81 37 -99.88 0.1446
2022-10-25 2022-09-30 13F VERTEX PHARMS Common Stock 92532F100 107,326 12,506 13.19 31,075 18.12 0.1331
2022-08-03 2022-06-30 13F VERTEX PHARMS Common Stock 92532F100 94,820 -12,091 -11.31 26,308 -5.71 0.1188
2022-05-04 2022-03-31 13F UNITED AIRLINES HLDGS Common Stock 92532F100 106,911 52,024 94.78 27,901 131.49 0.1193
2022-01-27 2021-12-31 13F VERTEX PHARMS Common Stock 92532F100 54,887 2,439 4.65 12,053 26.69 0.0468
2021-10-29 2021-09-30 13F VERTEX PHARMS Common Stock 92532F100 52,448 1,945 3.85 9,514 -6.57 0.0407
2021-07-26 2021-06-30 13F VERTEX PHARMS Common Stock 92532F100 50,503 -6,160 -10.87 10,183 -16.37 0.0449
2021-04-27 2021-03-31 13F VERTEX PHARMS Common Stock 92532F100 56,663 2,388 4.40 12,176 -5.08 0.0592
2021-01-25 2020-12-31 13F VERTEX PHARMS Common Stock 92532F100 54,275 -62,173 -53.39 12,827 -59.52 0.0620
2020-11-06 2020-09-30 13F VERTEX PHARMS Common Stock 92532F100 116,448 10,438 9.85 31,688 2.96 0.1807
2020-07-23 2020-06-30 13F VERTEX PHARMS Common Stock 92532F100 106,010 14,990 16.47 30,776 42.10 0.1945
2020-04-30 2020-03-31 13F VERTEX PHARMS Common Stock 92532F100 91,020 21,183 30.33 21,658 41.64 0.1714
2020-01-21 2019-12-31 13F VERTEX PHARMS Common Stock 92532F100 69,837 33,221 90.73 15,291 146.51 0.1004
2019-10-29 2019-09-30 13F VERTEX PHARMS Common Stock 92532F100 36,616 1,573 4.49 6,203 -3.47 0.0451
2019-07-29 2019-06-30 13F VERTEX PHARMS Common Stock 92532F100 35,043 -1,817 -4.93 6,426 -5.24 0.0493
2019-04-30 2019-03-31 13F/A-1 VERTEX PHARMS Common Stock 92532F100 36,860 -3,019 -7.57 6,781 2.62 0.0558
2019-04-30 2019-03-31 13F VERTEX PHARMS Common Stock 92532F100 39,879 0 6,608
2019-02-01 2018-12-31 13F VERTEX PHARMS Common Stock 92532F100 39,879 -3,639 -8.36 6,608 -21.22 0.0637
2018-11-05 2018-09-30 13F VERTEX PHARMS Common Stock 92532F100 43,518 8,117 22.93 8,388 39.41 0.0722
2018-07-24 2018-06-30 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 35,401 -1,324 -3.61 6,017 0.53 0.0579
2018-04-19 2018-03-31 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 36,725 5,262 16.72 5,985 26.94 0.0602
2018-02-14 2017-12-31 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 31,463 527 1.70 4,715 0.23 0.0490
2017-11-15 2017-09-30 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 30,936 4,086 15.22 4,704 35.95 0.0536
2017-07-27 2017-06-30 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 26,850 1,796 7.17 3,460 26.28 0.0432
2017-04-26 2017-03-31 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 25,054 5,935 31.04 2,740 94.60 0.0365
2017-02-13 2016-12-31 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 19,119 5,508 40.47 1,408 18.62 0.0212
2016-11-14 2016-09-30 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 13,611 8,400 161.20 1,187 80.95 0.0209
2016-08-05 2016-06-30 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 5,211 -6,405 -55.14 656 -28.93 0.0104
2016-05-10 2016-03-31 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 11,616 6,405 122.91 923 40.70 0.0242
2016-02-19 2015-12-31 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 5,211 1,876 56.25 656 89.05 0.0169
2015-11-16 2015-09-30 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 3,335 78 2.39 347 -13.68 0.0098
2015-08-04 2015-06-30 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 3,257 812 33.21 402 39.58 0.0084
2015-05-12 2015-03-31 13F/A-1 VERTEX PHARMACEUTICALS Common Stock 92532F100 2,445 270 12.41 288 11.63 0.0054
2015-04-30 2015-03-31 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 2,445 288
2015-02-10 2014-12-31 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 2,175 2,175 0.00 258 0.0052
2014-11-14 2014-09-30 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 0 -3,827 -100.00 0 -100.00
2014-08-13 2014-06-30 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 3,827 -733 -16.07 362 12.42 0.0079
2014-05-14 2014-03-31 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 4,560 1,525 50.25 322 43.11 0.0078
2014-02-19 2013-12-31 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 3,035 -332 -9.86 226 -99.91 0.0060
2013-11-14 2013-09-30 13F VERTEX PHARMACEUTICALS Common Stock 92532F100 3,367 3,367 255,286 0.0077
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.